Atyr Pharma Inc. (NASDAQ:LIFE) shot up 4.5% during trading on Wednesday . The company traded as high as $3.05 and last traded at $3.01, with a volume of 91,272 shares traded. The stock had previously closed at $2.88.

A number of research analysts have issued reports on LIFE shares. BMO Capital Markets started coverage on shares of Atyr Pharma in a research report on Monday, April 11th. They set a “market perform” rating on the stock. Zacks Investment Research downgraded shares of Atyr Pharma from a “hold” rating to a “sell” rating in a research report on Thursday, May 12th. Finally, William Blair downgraded shares of Atyr Pharma from an “outperform” rating to a “market perform” rating in a research report on Thursday, March 31st. Four analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. Atyr Pharma has a consensus rating of “Hold” and an average price target of $23.75.

The stock’s market cap is $73.43 million. The firm’s 50 day moving average price is $2.85 and its 200 day moving average price is $4.01.

Atyr Pharma (NASDAQ:LIFE) last posted its quarterly earnings results on Wednesday, May 11th. The company reported ($0.68) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.70) by $0.02. Analysts predict that Atyr Pharma Inc. will post ($2.79) earnings per share for the current fiscal year.

In related news, insider Grove Matsuoka purchased 12,412 shares of the company’s stock in a transaction that occurred on Wednesday, May 11th. The stock was acquired at an average price of $3.04 per share, with a total value of $37,732.48. Following the completion of the purchase, the insider now directly owns 2,412 shares in the company, valued at $7,332.48. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.